NCT02844660已完成不适用
A Multicenter, Prospective, Randomized, Controlled, Comparative Parallel Study of Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot Ulcers
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 130
- 试验地点
- 13
- 主要终点
- Study Safety Measurement
研究概览
简要总结
A Multicenter, Prospective, Randomized Controlled Comparative Parallel Study To determine the safety and effectiveness of EpiCord as compared to standard of care (SOC) therapy for the treatment of chronic, non-healing diabetic foot ulcers (DFUs)
详细描述
This is a prospective, multicenter, randomized controlled trial. The trial will include approximately 66 subjects in up to 10 experienced clinical centers in the United States. The estimated enrollment period is 18 weeks (this includes the 2-week run-in period). After completing a 2-week screening period, the subjects will be followed for at least 16 weeks post-randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has a known history of Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
- •Index ulcer characteristics:
- •a. Ulcer present for ≥ 30 days prior to randomization (Day 0) b. Index ulcer is located below the ankle c. Index ulcer area after debridement is ≥ 1 cm² and ≤ 15 cm² at the randomization visit
- •Subject has completed 14-day run-in period with ≤ 30% wound area reduction post-debridement.
- •Subject has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days:
- •Dorsum transcutaneous oxygen test (TcPO2) with results ≥ 30 mmHg, OR
- •ABIs with results of ≥ 0.7 and ≤ 1.2, OR
- •Doppler arterial waveforms, which are triphasic or biphasic at the ankle of the affected foot
- •The subject is willing and able to provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study
- •Index Ulcer Assessment:
- •Penetrates down totendon, or bone
- •Presence of another diabetic foot ulcer within 3 cm of the index ulcer
- •Index ulcer determined to be due to active Charcot deformity or major structural abnormalities of the foot
- •Exhibits clinical signs and symptoms of infection
- •Known or suspected local skin malignancy to the index diabetic ulcer
- •Wound duration > one year without intermittent closure
- •Prior therapies - Subjects receiving treatment with any of the following will not be eligible for enrollment:
- •In the last 7 days - Negative pressure wound therapy (wound vac or SNaP®) of the index ulcer
- •In the last 7 days - Hyperbaric oxygen (HBO) therapy
- •In the last 10 days - Chemical debridement, Dakin's solution, medical honey therapy
- •In the last 30 days - Treatment with cytotoxic chemotherapy, application of topical steroids to the ulcer surface, or use of ≥ 14 days of immune-suppressants (including systemic corticosteroids); or, subject is anticipated to require such medications during the course of the study
- •In the last 30 days - study ulcer treatment with any biological skin substitutes, including EpiCord, biomedical or topical growth factors, tissue engineered materials (e.g. Apligraf® or Dermagraft®), or other scaffold materials (e.g. OASIS® Wound Matrix, MatriStem® Wound Matrix, Grafix, etc.)
- •In the last 30 days - Subject has been on any investigational drug(s) or therapeutic device(s)
- •In the last 6 months - Amputation or revascularization (surgical or stenting) to the affected leg or foot
- •Subject criteria that will make subject ineligible for enrollment:
- •Known osteomyelitis or active cellulitis at wound site
- •Hemoglobin A1C >12 in the last 60 days prior to randomization
- •History of Immune system disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or HIV
- •Allergy or known sensitivity to Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate
- •Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator
- •Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)
- •Known history of poor compliance with medical treatments
- •Subjects currently enrolled in this study. Concurrent enrollment in the study is prohibited
- •Subjects currently receiving radiation therapy or chemotherapy
- •Patients currently on dialysis or planning to start dialysis
排除标准
- 未提供
研究组 & 干预措施
Standard of Care
Active Comparator
Weekly application of moist wound therapy and offloading
干预措施: Standard of Care (Other)
EpiCord
Experimental
Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
干预措施: EpiCord (Biological)
结局指标
主要结局
Study Safety Measurement
时间窗: 12 weeks
The proportion of product related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events at 12 weeks.
Complete Ulcer Closure
时间窗: 12 weeks
The percentage of subjects with complete closure of the study ulcer as assessed by photographic evaluation
次要结局
- Rate of wound closure(up to 12 weeks)
- Time to complete closure(up to 12 weeks)
- Incidence of ulcer recurrence(up to 12 weeks)
- Quality of Life Health Survey(up to 12 weeks)
- Quality of Life-Pain(up to 12 weeks)
- Cost effectiveness of treatment(up to 12 weeks)
研究者
研究点 (13)
Loading locations...
相似试验
终止
不适用
Chondro-Gide® Bilayer Collagen Membrane in Knee Cartilage Defect RepairCartilage DefectsNCT05785949Geistlich Pharma AG75
已完成
2 期
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of MigraineAcute MigraineNCT02745392Zosano Pharma Corporation365
已完成
3 期
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell LymphomaLymphoma, Large B-Cell, DiffuseNCT01649856Hoffmann-La Roche572
已完成
不适用
New Dermal Filler for Chin Correction and AugmentationChin Augmentation and CorrectionNCT04631263Galderma R&D140
撤回
不适用
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot UlcersDiabetic Foot UlcerNCT05024656Integra LifeSciences Corporation